FDA decision: Lorundrostat by Mineralys Therapeutics (on or before December 22, 2026)Yes87%No21%$70 volView details
FDA decision: Ralinepag by United Therapeutics (on or before June 24, 2027)Yes83%No25%$41 volView details
FDA decision: Tozorakimab by AstraZeneca (on or before March 31, 2027)Yes80%No28%$308 volView details
FDA decision: Ulixacaltamide by Praxis Precision Medicines (on or before January 29, 2027)Yes77%No32%$0 volView details